Alzamend Neuro, Inc. (ALZN) News
Follow Alzamend Neuro, Inc. (ALZN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Alzamend Neuro presents Phase 1/2A 7T lithium imaging results showing trends favoring AL001
Alzamend Neuro presented Phase 1/2A 7T brain pharmacokinetic imaging data showing trends toward higher brain lithium levels and AUC for AL001 versus lithium carbonate.Key Highlights:Original SEC Filing: Alzamend Neuro, I
REGULATION | Sep 29, 2026, 10:33 AM UTC
H
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, cont
EARNINGS | Sep 14, 2026, 09:01 PM UTC
H
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
EARNINGS | Sep 11, 2026, 08:03 PM UTC
M
Alzamend Neuro posts $3.03M quarterly net loss
For the quarter ended July 31, 2026, Alzamend Neuro reported a net loss of $3.03M and diluted net loss per share of $(0.68). The company recorded no product revenue.
EARNINGS | Sep 10, 2026, 08:42 PM UTC
M
ALZN reports $3.0 million quarterly net loss and $7.6 million cash
ALZN said its net loss widened to $3.0 million for the quarter. The company reported cash increased to $7.6 million after equity financing, while citing substantial doubt about continuing as a going concern.
EQUITY | Sep 10, 2026, 08:35 PM UTC
L
Alzamend Neuro expected loss of 56 cents a share
Alzamend Neuro Inc is expected to post a loss of 56 cents a share.
EARNINGS | Sep 04, 2026, 08:07 PM UTC
L
Alzamend Neuro’s Phase 1/2A lithium neuroimaging data accepted for poster
Alzamend Neuro’s Phase 1/2A lithium neuroimaging data has been accepted for poster presentation at Neuroscience 2026 in Washington, DC, per TradeXchange Newsdesk.
EQUITY | Aug 20, 2026, 12:01 PM UTC
L
Alzamend Neuro lithium imaging data accepted for oral presentation
Alzamend Neuro says its Phase 1/2A lithium imaging data has been accepted for an oral presentation at the ISMRM Workshop on X-Nuclei MR in Barcelona, Spain.
EQUITY | Aug 18, 2026, 12:01 PM UTC
L
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17
EQUITY | Jul 01, 2026, 12:05 PM UTC
L
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ: ALZN ) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ: VVOS ) shares increased by 9.92
GEOPOLITICS | Jun 30, 2026, 09:05 PM UTC